Represents the additional contribution amount to a collaboration.

No definition available.

Name:	abbv_AdditionalContributionToCollaboration
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the additional contribution amount to a collaboration by partner.

+ References

No definition available.

+ Details

Name:	abbv_AdditionalContributionToCollaborationByPartner
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the consideration received from a counterparty for reacquired rights.

+ References

No definition available.

+ Details

Name:	abbv_ConsiderationFromCounterpartyForReacquiredRights
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.

+ References

No definition available.

+ Details

Name:	abbv_PotentialPaymentsUnderAgreementCertainMilestones
Namespace Prefix:	abbv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the term by which the agreement was extended.

+ References

No definition available.

+ Details

Name:	abbv_TermByWhichTheAgreementWasExtended
Namespace Prefix:	abbv_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherOperatingIncomeExpenseNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash outflow to acquire investments classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_ReataPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_CalicoLifeSciencesLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_AlectorIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abbv_OtherCollaborationArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Cash outflows related to other acquisitions and investments				$ 1,135	$ 736	$ 308
Acquired in-process research and development				385	424	327
Other operating expense (income)				890	(500)	0
Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Additional contribution to collaboration		$ 500
Reata Pharmaceuticals Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Other operating expense (income)			$ 330
Calico Life Sciences LLC \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Additional contribution to collaboration by partner		$ 500
Term by which the agreement was extended		3 years
Other operating expense (income)					(500)
Alector, Inc. \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired in-process research and development						205
Potential additional milestone payments			986	986
Other individually insignificant arrangements \| Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired in-process research and development				385	$ 424	$ 122
Other individually insignificant arrangements \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments			$ 5,800	$ 5,800
Other operating income \| Reata Pharmaceuticals Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Consideration receivable for reacquired rights	$ 330